Immutep Limited

IMMP: 20-F · periodic report

Immutep filed its FY2026 annual report (fiscal year ended June 30, 2026) showing a net loss of A$79.3 million, widened from A$61.4 million a year earlier, with no products approved for commercial sale. The most significant clinical development was the March 2026 discontinuation of TACTI-004, the registrational Phase III trial of lead asset eftilagimod alfa in 1st line NSCLC, after a planned interim futility analysis. This triggered an A$3.1 million non-cash impairment of efti-related IP, and an ongoing root cause analysis identified subtle structural differences between 2,000L and 200L scale manufactured efti as potentially relevant to the failed outcome. During the year, Immutep signed a strategic licensing deal with Dr. Reddy's Laboratories covering efti in all markets outside its own territory, with potential milestones of up to US$349.5 million plus royalties, while Novartis terminated the IMP701 (ieramilimab) license in August 2026. The company also cured a Nasdaq minimum bid price deficiency by changing its ADS ratio to 1 ADS per 200 ordinary shares effective September 28, 2026, and flags reliance on WuXi Biologics manufacturing against potential BIOSECURE Act restrictions as a key supply-chain risk.

SEC 20-F•2d ago

IMMP: 6-K · reverse split

Immutep announced a change to its ADS ratio, effective at the open on 28 September 2026: from 1 ADS = 10 ordinary shares to 1 ADS = 200 ordinary shares, equivalent to a 1-for-20 reverse split for ADS holders. The number of ordinary shares (1,473,721,306) and ASX holdings are unchanged, with no dilution or shareholder approval required. The move is a technical step to regain compliance with Nasdaq's US$1.00 minimum bid price rule, after Immutep was notified on 30 April 2026 that its ADSs traded below US$1.00 for 30 consecutive business days. The ADS must close at or above US$1.00 for at least 10 consecutive business days before the compliance period ends on 26 October 2026. New ADS CUSIP 45257L207 replaces 45257L108, with roughly 1.64 million ADSs outstanding post-change versus about 32.8 million before; fractional entitlements will be paid in cash by BNY with no fee. The Board said it set a generous margin above US$1.00 because a repeat deficiency within 12 months would not earn a new compliance period.

SEC 6-K•1mo ago

IMMP: 6-K · periodic report

Immutep filed its FY2026 annual results (year ended 30 June 2026) via 6-K, reporting a net loss after tax of A$79.3 million, up 29.1% from A$61.4 million in FY2025, with a basic loss per share of 5.39 cents versus 4.22 cents. Total revenue and other income more than doubled to A$24.2 million — the highest in a decade — driven by A$14.6 million of license revenue from partner Dr Reddy's. Immutep received a US$20 million upfront payment in January 2026 and repaid US$10 million of it in June 2026 following the discontinuation of its Phase III TACTI-004 study. R&D and IP expenses rose to A$91.9 million, including a A$3.1 million non-cash impairment of the efti patent intangible, and operating cash outflow was A$55.5 million. The company held A$68.9 million in cash and term deposits at year-end, affirmed going concern, and expects significantly lower losses in FY2027 after cost reductions and headcount cuts tied to the TACTI-004 wind-down. A key watch item: in April 2026 Immutep received a Nasdaq notice that its ADSs no longer meet the US$1.00 minimum bid price requirement, with a 180-day compliance window expiring on 26 October 2026. Management also made Dr Stephan Winckels permanent Chief Medical Officer effective 1 July 2025.

SEC 6-K•1mo ago